Form 4 for EW Edwards Lifesciences
Accepted 2023-08-09 00:00:00 ET · period of report 2023-08-09 · accession 0001225208-23-008138 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-09 | 2023-08-09 | EW | Szyman Catherine M. | CVP, Critical Care | S - Sale+OE | $78.64 | -5,000 | 34.8K | -13% | -$393.2K |
| D | 2023-08-09 | 2023-08-09 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $36.75 | +5,000 | 39.8K | +14% | +$183.8K |
| D | 2023-08-09 | 2023-08-09 | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $0.00 | -5,000 | 57.0K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-09 | S | D | 5,000 | $78.64 | 34,813.57 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $78.44 to $78.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2023-08-09 | M | A | 5,000 | $36.75 | 39,813.57 | D | — | — | |
| 3 | Derivative | Employee Stock Option (Right to Acquire) | 2023-08-09 | M | D | 5,000 | $0.00 | 57,000 | D | $36.75 · 2018-05-11 to 2024-05-10 | 5,000 Common Stock |